TY - JOUR
T1 - Low-grade serous ovarian carcinoma
T2 - A retrospective study on 34 complete cytoreductive surgeries
AU - Zaccarini, F.
AU - Roosen, A.
AU - Sanson, C.
AU - Maulard, A.
AU - Scherier, S.
AU - Pautier, P.
AU - Leary, A.
AU - Chargari, C.
AU - Morice, P.
AU - Gouy, S.
N1 - Publisher Copyright:
© 2021 Elsevier Masson SAS
PY - 2021/10/1
Y1 - 2021/10/1
N2 - Aim of the study: Low-grade serous ovarian cancer is a distinct, slow-growing entity that affects mainly young women. The objective of this study was to describe the clinical characterisitics and survival outcomes of a population of patients suffering from advanced stage CSBG. Patients and methods: A retrospective study was carried out in patients with advanced stage ovarian CSBG (FIGO IIIb-IV) who had complete macroscopic cytoreductive surgery, at Gustave Roussy Institut, Villejuif, between 2004 and 2017. Results: Thirty-four patients were included, who were mainly young women (mean age 41.3 years), diagnosed at FIGO stage IIIC (91 %). The median follow-up was 41 months. Neoadjuvant chemotherapy was administered in 16 patients (47.1 %), and complete response never occurred. Upper abdominal surgical procedures were necessary in 90 % of cases and a bowel resection was performed in more than 80 % of cases. Over 90 % of patients received adjuvant chemotherapy followed by maintenance treatment with bevacizumab in over 40 % of cases. During follow-up, 9 (26 %) deaths occurred. Five-year overall survival was 70 % and disease-free survival was 20 %. Conclusion: CSBG of the ovary has a low chemosensitivity and requires maximum surgical management, which should be performed in expert centers.
AB - Aim of the study: Low-grade serous ovarian cancer is a distinct, slow-growing entity that affects mainly young women. The objective of this study was to describe the clinical characterisitics and survival outcomes of a population of patients suffering from advanced stage CSBG. Patients and methods: A retrospective study was carried out in patients with advanced stage ovarian CSBG (FIGO IIIb-IV) who had complete macroscopic cytoreductive surgery, at Gustave Roussy Institut, Villejuif, between 2004 and 2017. Results: Thirty-four patients were included, who were mainly young women (mean age 41.3 years), diagnosed at FIGO stage IIIC (91 %). The median follow-up was 41 months. Neoadjuvant chemotherapy was administered in 16 patients (47.1 %), and complete response never occurred. Upper abdominal surgical procedures were necessary in 90 % of cases and a bowel resection was performed in more than 80 % of cases. Over 90 % of patients received adjuvant chemotherapy followed by maintenance treatment with bevacizumab in over 40 % of cases. During follow-up, 9 (26 %) deaths occurred. Five-year overall survival was 70 % and disease-free survival was 20 %. Conclusion: CSBG of the ovary has a low chemosensitivity and requires maximum surgical management, which should be performed in expert centers.
KW - Cytoreductive surgery
KW - Low-grade serous ovarian cancer
KW - Outcomes
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85106363830&partnerID=8YFLogxK
U2 - 10.1016/j.gofs.2021.04.009
DO - 10.1016/j.gofs.2021.04.009
M3 - Article
C2 - 33933671
AN - SCOPUS:85106363830
SN - 2468-7197
VL - 49
SP - 750
EP - 755
JO - Gynecologie Obstetrique Fertilite et Senologie
JF - Gynecologie Obstetrique Fertilite et Senologie
IS - 10
ER -